Pharma BD Deal Intelligence

Roche Holding AG / Santaris Pharma A/S

2014 · Acquisition/Merger · $450M · Complete

Announcement Sentiment

Strongly positive

Roche acquired Copenhagen-based Santaris Pharma for $250M cash up front plus up to $200M in milestones, gaining the LNA antisense oligonucleotide platform. Strengthened Roche's RNA-targeted drug-discovery capabilities alongside its Genentech antibody franchise.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Aug 21, 2014
Closed Sep 30, 2014
Deal value $450M
Deal type Acquisition/Merger
Therapeutic area Multiple (platform deal)
Indications Multiple (platform deal)
Key assets Locked Nucleic Acid (LNA) antisense platform
Mechanism Locked nucleic acid antisense oligonucleotide drug discovery

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals